References
Akehurst RL. Making decisions on technology availability in the British National Health Service: why we need reliable models. Value Health 2003 Jan–Feb; 6 (1): 3–5
Chilcott J, Brennan A, Booth A, et al. The role of modelling in prioritising and planning clinical trials. Health Technol Assess 2003; 7 (23): iii, 1–125
Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355–71
Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices — Modeling Studies. Value Health 2003 Jan–Feb; 6(1): 9–17
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
Karnon J, Brennan A, Akehurst R. A critique and impact analysis of decision modeling assumptions. Med Decis Making 2007 Jul–Aug; 27 (4): 491–9
Evans C, Crawford B. Expert judgement in pharmacoeconomic studies: guidance and future use. Pharmacoeconomics 2000 Jun; 17 (6): 545–53
Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997 Jan; 2 (1): 26–30
Vallejo-Torres L, Steuten LM, Buxton MJ, et al. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach. Int J Technol Assess Health Care 2008 Fall; 24 (4): 459–64
Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008 Feb 2; 336 (7638): 251–4
Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making 2008 Jan–Feb; 28 (1): 21–32
Payne K. Fish and chips all round? Regulation of DNA-based genetic diagnostics. Health Econ 2009 Nov; 18 (11): 1233–6
National Institute for Health and Clinical Excellence. Diagnostics assessment programme: interim methods statement. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/aboutnice/whatwedo/aboutdiagnosticsassessment/?domedia=1&mid=09ECD2A3-19B9-E0B5-D480B5D3F5A9CD76 [Accessed 2010 Sep 9]
Lindqvist P, Nordanger UK. (Mis-?) using the E-Delphi method: an attempt to articulate the practical knowledge of teaching. J Res Methods Methodological Issues 2007; 1 (1) [online]. Available from URL: http://www.scientificjournals.org/journals2007/articles/1222.pdf [Accessed 2011 Mar 14]
Goodman CM. The Delphi technique: a critique. J Adv Nurs 1987 Nov; 12 (6): 729–34
Rauch W. The decision Delphi. Technol Forecast Soc Change 1979; 15: 159–69
Franklin KK, Hart JK. Idea generation and exploration: benefits and limitations of the policy Delphi research method. Innov High Educ 2007; 31: 237–46
Shabaruddin FH, Elliott RA, Valle JW, et al. Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. Br J Cancer 2010 Jul 27; 103 (3): 315–23
Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. Epub 2009 Jan 9
Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005 Apr; 14 (4): 339–47
O’Hagan A, Buck CE, Daneshkhah A, et al. Uncertain judgements: eliciting experts’ probabilities. Hoboken (NJ): John Wiley & Sons, 2006
Leal J, Wordsworth S, Legood R, et al. Eliciting expert opinion for economic models: an applied example. Value Health 2007 May–Jun; 10 (3): 195–203
Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 799–806
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sullivan, W., Payne, K. The Appropriate Elicitation of Expert Opinion in Economic Models. Pharmacoeconomics 29, 455–459 (2011). https://doi.org/10.2165/11589220-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11589220-000000000-00000